Valuation & Earnings
This table compares Carmell and Acutus Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carmell | $32,839.00 | 343.12 | -$15.44 million | ($0.46) | -1.17 |
| Acutus Medical | $7.16 million | 0.00 | -$81.66 million | ($0.11) | 0.00 |
Carmell has higher earnings, but lower revenue than Acutus Medical. Carmell is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Carmell | N/A | -217.50% | -50.22% |
| Acutus Medical | -272.74% | -311.64% | -11.57% |
Insider & Institutional Ownership
24.2% of Carmell shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 29.0% of Carmell shares are held by insiders. Comparatively, 5.2% of Acutus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Acutus Medical has a beta of -1.32, meaning that its share price is 232% less volatile than the S&P 500.
Summary
Carmell beats Acutus Medical on 6 of the 11 factors compared between the two stocks.
About Carmell
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
About Acutus Medical
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.
